Patents by Inventor David R. Sibley
David R. Sibley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312511Abstract: The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula I together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula I is administered to the patient together with one or more additional active agents.Type: ApplicationFiled: February 17, 2023Publication date: October 5, 2023Inventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Patent number: 11634404Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.Type: GrantFiled: April 14, 2017Date of Patent: April 25, 2023Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF KANSAS, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILLInventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Publication number: 20210323941Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.Type: ApplicationFiled: April 14, 2017Publication date: October 21, 2021Inventors: David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
-
Publication number: 20210040074Abstract: Disclosed are compounds of formulas (I) and (III) for treating or preventing a disease or disorder responsive to activation of a D1 dopamine receptor agonist in a mammal in need thereof, wherein m, n, R1-R6, and R11-R13 are as defined herein. Examples of such disease or disorder include Alzheimer's Disease, schizophrenia, Parkinson's disease, a dyskinesia, and Huntington's disease.Type: ApplicationFiled: March 6, 2019Publication date: February 11, 2021Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Kansas, The University of North Carolina at Chapel HillInventors: David R. Sibley, Kathryn D. Luderman, Jennie L. Conroy, R. Benjamin Free, Prashi Jain, Noel T. Southall, Marc Ferrer, Jeffrey Aubé, Kevin Frankowski
-
Patent number: 6844190Abstract: Genes encoding the St-B17 serotonin receptor protein were cloned and characterized from a rat striatum mRNA and a human genomic library. The St-B17 receptor has nucleotide and amino acid homology with previously described 5-HT genes and can bind ligands that are known to interact with serotonin receptors. In addition, the levels of intracellular cAMP in cells transfected with the receptor gene respond in a dose dependent manner to introduction of serotonin in the media.Type: GrantFiled: April 10, 2001Date of Patent: January 18, 2005Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David R. Sibley, Frederick J. Monsma, Jr., Mark Hamblin
-
Publication number: 20020091235Abstract: Genes encoding the St-B17 serotonin receptor protein were cloned and characterized from a rat striatum mRNA and a human genomic library. The St-B17 receptor has nucleotide and amino acid homology with previously described 5-HT genes and can bind ligands that are known to interact with serotonin receptors. In addition, the levels of intracellular cAMP in cells transfected with the receptor gene respond in a dose dependent manner to introduction of serotonin in the media.Type: ApplicationFiled: April 10, 2001Publication date: July 11, 2002Inventors: David R. Sibley, Frederick J. Monsma, Mark Hamblin
-
Patent number: 5914236Abstract: The PCT-65 serotonin receptor gene was cloned and characterized from rat and human libraries. This receptor has nucleotide and amino acid homology with previously described 5-HT genes and can bind ligands that are known to interact with serotonin receptors.Type: GrantFiled: September 18, 1995Date of Patent: June 22, 1999Assignee: United States of AmericaInventors: Frederick J. Monsma, Jr., Yong Shen, David R. Sibley, Mark Hamblin
-
Patent number: 5610282Abstract: The present invention relates to the molecular cloning and expression of the D.sub.1 dopamine receptor protein that is linked to the activation of adenylyl cyclase activity. By constructing cell lines that express the D.sub.1 receptor, the affinities and efficacies of agonist and antagonist drugs with the receptor can be assessed.The present invention further relates to a recombinant DNA construct that includes a vector and a DNA fragment encoding the D.sub.1 receptor. The present invention also relates to a host cell transformed with a recombinant DNA construct, so that the DNA fragment is expressed and the D.sub.1 receptor is produced. Suitable expression systems include eukaryotic and procaryotic cells, especially mammalian cells such as rat or human.The present invention further relates to the antibody to the D.sub.1 receptor protein. For diagnostic purposes, antibodies to this receptor can be prepared by producing all or a portion of the receptor protein and injecting these into various types of mammals.Type: GrantFiled: May 19, 1995Date of Patent: March 11, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: David R. Sibley, Frederick J. Monsma, Lawrence C. Mahan, Loris D. McVittie
-
Patent number: 5552289Abstract: In the present investigation, we report the identification and cloning of a cDNA encoding an RNA splice variant of the rat D.sub.2 receptor CDNA.sup.12. This cDNA codes for a receptor isoform which is predominantly expressed in the brain and contains an additional 29 amino acids in the 3rd cytoplasmic loop, a region believed to be involved with G protein coupling. This is the first example of a novel G-protein coupled receptor isoform generated by alternative RNA splicing.Type: GrantFiled: August 3, 1993Date of Patent: September 3, 1996Assignee: United States of AmericaInventors: David R. Sibley, Frederick J. Monsma, Jr., Loris D. McVittie, Lawrence C. Mahan
-
Patent number: 5128254Abstract: In the present investigation, we report the identification and cloning of a cDNA encoding an RNA splice variant of the rat D.sub.2 receptor cDNA.sup.12. This cDNA codes for a receptor isoform which is predominantly expressed in the brain and contains an additional 29 amino acids in the 3rd cytoplasmic loop, a region believed to be involved with G protein coupling. This is the first example of a novel G-protein coupled receptor isoform generated by alternative RNA splicing.Type: GrantFiled: November 1, 1989Date of Patent: July 7, 1992Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: David R. Sibley, Frederick J. Monsma, Jr., Loris D. McVittie, Lawrence C. Mahan